The synthesis and biological evaluation of sixteen-membered macrolides modified at the C-3 position are described. 3-Epi-leucomycin A7 (9), 3-O-acyl-3-epi-leucomycin A7 analogues (11a-11e), 3-O-acylleucomycin A7 analogues (13b-13e) and 3-O-methylleucomycin analogues (16a, 16b and 22) were synthesized via fully protected intermediates (7, 5a, 5b and 20) . After appropriate modification, subsequent deprotections were performed to furnish a variety of leucomycin analogues. Methylation of the 3-hydroxyl group was found to improve the pharmacoprofile of leucomycin antibiotics. 3-O-Methylrokitamycin (16b) showed enhanced antibacterial activity in vitro and 3,3"-di-O-methyl-4"-O- (3-methylbutyl) (ABT 773)10, 11) , is now at the late stage of clinical trial. Although these ketolides exhibit strong potency against not only erm inducible resistant strains o S. pneumoniae but also erm constitutive resistant strains, they are still exposed to the menace of resistant S. pneumoniae with efflux pump. On the other hand, some of the sixteen-membered macrolides, such as miokamycin (MOM)12,13) and rokitamycin (RKM)14-15) ( Fig. 1) are not affected by efflux pumps. In addition, these two semisynthetic sixteen-membered macrolide antibiotics have been already proven to be safe in clinical use. Thus, drug discovery in the field of sixteen-membered macrolides is important for antiinfective chemotherapy in the future. Background In the leucomycin family, 3-OH type derivatives exhibit stronger antibiotic activities than corresponding 3-O-acyl analogues. However, the biological stability of these two groups has not been fully discussed because of complexity of their metabolism at the neutral sugar moiety. We first synthesized 3-epi-leucomycin A7 (9) from leucomycin A7 (LM-A7, Fig. 1 )19 as shown in Scheme 1.
LM-A7 was prepared from midecamycin A1 (MDM, Fig.   1 )20,21) via biotransformation using PF 1083 on a large scale21). There were mainly two synthetic strategies for preparation of 9. One of them was SN2 substitution of the 3-hydroxyl group (including Mitsunobu reaction) and the other was stereoselective reduction of 3-dehydro ( introducing acyl groups in an attempt to improve both antibacterial activity and biological stability. As illustrated in Scheme 2, acyl side chains were introduced to 7 to give 10a-10e. Deprotections were carried out to furnish 3-Oacyl-3-epi-LM-A7 derivatives (11a-11e).
As shown in Scheme 3, we also synthesized 3-O-acyl-LM-A7 derivatives (13b-13e) with natural stereochemistry at the C-3 position.
Biological Evaluation of Novel

3-O-Acylleucomycins
In vitro antibacterial activities of 3-epi-LM-A7 (9), 3-Oacyl-3-epi-LM-A7 analogues (11a-11e) and their corresponding compounds (LM-A7, MDM, 13b-13e) with natural stereochemistry at the C-3 position are shown in Unfortunately, stability of 9 in rat plasma was significantly decreased compared with that of LM-A7 even in the preliminary study. Thus, T1/2 of 9 was approximately eight times shorter than that of LM-A7 (data not shown).
With these results, however, we reconfirmed that modification at the C-3 position was practically important for both antibacterial activity and metabolic stability.
Synthesis of 3-O-Methylleucomycins
In 3-O-acyl derivatives, suppression of lactone opening by the C-3 side chain must be one of the reasons for their stability. Thus, we conducted methylation of the 3-hydroxyl group to donate the steric hindrance to the lactone ring. 3carbonyl more efficiently than an acyl group. Additionally, undesirable 3,18-hemiacetal formation can be avoided by masking the 3-hydroxyl group. Thus, this modification can be one of the most promising approaches in drug discovery of sixteen-membered macrolides. Although there is one example27) of methylation of the 3-hydroxyl group in platenolide skeleton, precise SAR information has not been discussed so far. Although 22 and 1 exhibited almost the same antibacterial activities (Table 2) , biological stability of 22 was improved. Actually, 22 was almost intact in rat plasma as we first approximately two times more stable than 1 in preliminary experiments. Thus, 22 was proposed to be one of the most biologically stable sixteen-membered macrolides with strong antibacterial activities. From these results, we can conclude that methylation of the 3-hydroxyl group is one of the most promising modification of sixteen-membered macrolides for the improvement of their pharmacoprofiles.
As shown in
Conclusion
On the basis of the reported structure of a metabolite of spiramycin I and biological properties of our in-house compounds (Fig. 2, 1 and 2), we synthesized and evaluated a variety of 3-epi-leucomycin analogues (9, 11a-11e) along with 3-O-acyl compounds with a natural stereo center at the C-3 position (13b-13e). As a result, we reconfirmed that the C-3 position is important for pharmacoprofiles in the leucomycin family. brine. Then the organic layer was dried and concentrated to afford crude 3 along with 9,18-bis-O-TBS-LM-A7 3,18acetal. This mixture was used for the next step without purification.
To a stirred solution of 3 and 9,18-bis-O-TBS-LM-A7 3,18-acetal in THF (300ml) was added tetrabutylammonium fluoride (1.0M in THF, 22.9ml, 22.9mmol). After stirring for 3 hours at room temperature, 5% aqueous KHSO4 was added and the aqueous layer was extracted with EtOAc. The extract was washed with water, saturated aqueous NaHCO3 and brine. The organic layer was dried and concentrated to give crude 3 (14.3g) which was used for the next step without purification.
To a stirred solution of crude 3 (14.3g) in MeOH (120ml), trimethyl orthoformate (120ml) and pyridinium p-toluenesulfonate (5.94g, 23.6mmol) were added and the Evaporation gave a residue which was diluted with EtOAc and the extract was washed with saturated aqueous NaHCO3 and brine. The organic layer was dried with MgSO4 and concentrated to afford crude 4 (37.1g) which was used for the next step without purification.
To a stirred solution of crude 4 (37.1g) in MeCN (200ml) was added acetic anhydride (7.50ml, 79.5mmol) and the reaction mixture was stirred for 24 hours at room temperature. Saturated aqueous NaHCO3 were added and the mixture was evaporated. The aqueous layer was extracted with EtOAc and the extract was washed with saturated aqueous NaHCO3 and brine. After the organic layer was dried and concentrated, the residue was purified by silica gel chromatography [750g, hexane-EtOAc (1:1)] to afford 5a (8.23g, 62% overall 4 steps). CH3), 1.11 (d, 6"-H), 1.16 (t, 4"-OCOCH2CH3), (6) added 5a (1.51g, 1.57mmol) in CH2Cl2 (8.0ml). After 15.8mmol) was added and the mixture was gradually warmed to room temperature. Saturated aqueous NaHCO3 was added and the aqueous layer was extracted with CHCl3.
The extract was washed with brine, dried and concentrated. The residue was purified by silica gel chromatography [300g, benzene-acetone (20:1-15:1)] to give 6 (448mg, 30%). This was a equilibrium mixture of keto and trans enol tautomer (ca. 1:1). (dd, 10-H), 6.04 (dd, 11-H).
19-H
2'-O-Acetyl-9-O-(tert-butyldimethylsilyl)-3-epi-leucomycin A7 18-Dimethylacetal (7) dioxane (8.0ml), NaBH4 (65.0mg, 1.72mmol) was added and the mixture was stirred overnight at room temperature.
Water was added and the aqueous layer was extracted with CHCl3. The organic layer was washed with brine, dried and concentrated. The residue was purified by silica gel chromatography [50g, hexane-EtOAc (2:1-1:1)] to give 7 (259mg, 75%). 
3-Epi-3-O-propionylleucomycin A7 (11a)
By similar procedures to 9, reactions of 10a gave crude 11a. This was purified by preparative TLC [CHCl3-MeOH-NH4OH (400:20:1)] to afford 11a (69% overall 2 steps). 
3-O-Benzoyl-3-epi-leucomycin A7 (lib)
By similar procedures to 9, reactions of 10b gave crude MeOH-NH4OH (150:1:1)] to afford lib (55% overall 2 steps). By a similar procedure to 10a, reaction of 5a and cyclohexylcarbonyl chloride gave crude 12c. This was purified by silica gel chromatography [hexane-EtOAc (5:1-3:1)] to give 12c (72%).
(s, 3"-CH3), 1.12 (d, 6"-H), 1.16 (t, 4"-OCOCH2CH3), 1.23 (d, 16-H), 1.24 (d, 6'-H), 1.44 (dq, 3-OCOC6H11), 1.64 (m, 3-OCOC6H11), 1.74 (m, 3-OCOC6H11), 1.83 (dd, 2"-Hax), 1.92 (br d, 3-OCOC6H 11), 2.00 (d, 2"-Heq), 2.00 (s, 2'-OCOCH3), 2.10 (dt, 14-H), 2.22 (br d, 2-H), 2.31 (tt, 3-OCOC6H11), 2.39 (s, 3'-N(CH3)2), 2.42 (q, 4"-OCOCH2CH3), 2.43 (q, 4"-OCOCH2CH3), 2.68 (dd, 2-H), 2.70 (t, 3'-H), 3.13 (br d, 4-H (br dd,12-H), 6.31(dd, 11-H).
2'-O-Acetyl-9-O-(tert-butyldimethylsilyl)-3-O-(6phenylhexanoyl)leucomycin A7 18-Dimethylacetal (12d) By a similar procedure to 10a, reaction of 5a and 6phenylhexanoyl chloride gave crude 12d. This was purified by silica gel chromatography [hexane-EtOAc (5:1-3:1-1:1)] to give 12d (64%). 
3-O-Benzoylleucomycin A7 (13b)
By similar procedures to 9, reactions of 12b gave crude 13b. This was purified by preparative TLC [CHCl3-MeOH (20:1)] to afford 13b (42% overall 2 steps). 3.19 (m, 3.22 (t, 3.31 (dd, 3.52 (dd, 3.56 (s, 3.81 (br d, 4.17 (dd, 4.32 (d, 4.43 (dq, 4.59 (d, 5.01 (d, 5.06 (ddq, 5.37 (br d, 5.67 (dd, 5.78 (ddd, 13-H), 6.09 (br dd, 12-H), 6.67 (dd, 11-H), 7.43 (br t, 3-OCOC6H5), 7.54 (tt, 3-OCOC6H5), 8.06 (br d, 3-OCOC6H5), 9.52 (br s,18-H).
3-O-(Cyclohxylcarbonyl)leucomycin A7 (13c)
By similar procedures to 9, reactions of 12c gave crude 13c. This was purified by preparative TLC [CHCl3 -MeOH-NH4OH (100:10:1)] to afford 13c (55% in 2 steps).
1.11 (d, 6"-H), 1.16 (t, 4"-OCOCH2CH3), 1.20 (d, 6'-H), 1.24 (d, 16-H), 1.45 (br dq, 3-OCOC6H11), 1.45 (m, 7-H), 1.63 (m, 3-OCOC6H11), 1.74 (m, 3-OCOC6H11), 1.82 (dd, 2"-Hax), 1.90 (m, 8-H), 1.99 (d, 2"-Heq), 2.03 (m, 3-OCOC6H11), 2.12 (dt, 14-H), 2.24 (br d, 2-H), 2.33 (br dd, 17-H), 2.42 (q, 4"-OCOCH2CH3), 2.43 (q, 4"-OCOCH2CH3), 2.49 (s, 3'-N(CH3)2), 2.74 (dd, 2-H), 2.76 (br dd,17-H), 3.22 (dd, 4-H), 3.25 (t, 4 '-H), 3.51(dd, 2'-H), 3.51 (s, 4-OCH3), 3.79 (br d, 5-H), 4.09 (dd, 9-H), 4.38 (d, 1'-H), 4.44 (dq, 5"-H), 4.60 (d, 4"-H), 5.01 (ddq, 15-H), 5.05 (d, 1"-H), 5.10 (br d, 3-H), 5.61 (dd, 10-H), 5.74 (ddd, 13-H), 6.05 (br dd, 12-H), 6.59 (dd, 11-H), 9.64 (br s, 18-H) .
3-O-(6-Phenylhexanoyl)leucomycin A7 (13d)
By similar procedures to 9, reactions of 12d gave crude 13d. This was purified by preparative TLC [CHCl3-MeOH-NH4OH (100:10:1)] to afford 13d (37% overall 2 steps). 
3-O-Methylleucomycin A7 (16a)
MeOH-H2O (9:1) was stirred overnight at room temperature. The reaction mixture was concentrated and the crude 15a was diluted in 4.0ml of MeCN-H2O (1:1). To organic layer was washed with saturated aqueous NaHCO3 and brine, dried and concentrated. The residue was purified by preparative TLC [hexane-EtOAc (1:1)] to afford 16a (4.0mg, 22% overall 2 steps). (ddd, 13-H), 6.05 (br dd, 12-H), 6.23 (dd, 11-H), 9.77 (br s, 18-H).
3-O-Methylrokitamycin (16b)
By similar procedures to 9, reactions of 14b gave crude 16b via 15b. The crude 16b was purified by preparative TLC [CHCl3-MeOH-NH4OH (200:10:1)] to afford 16b (66% overall 2 steps). (20) To 17 (510mg, 0.503mmol) was added tetrabutylammonium fluoride (1.0M in THF, 2.5ml, 2.5mmol) and the reaction mixture was stirred for 15 minutes at room temperature. The reaction mixture was diluted with CH2Cl2 and the organic layer was washed with brine, dried and concentrated. The residue was purified by silica gel chromatography [30g, CHCl3-MeOH (10:1)] to give crude 18 (440mg) which was used for the next step without further purification.
To a stirred solution of 18 (50.0mg) in MeOH (1.0ml), trimethyl orthoformate (1.0ml) and pyridinium pwas diluted with CH2Cl2 and washed with saturated NaHCO3 and brine. The organic layer was dried and concentrated to give 19 which was used for the next step without purification.
To a stirred solution of 19 in MeCN (1.0ml), acetic diluted with CH2Cl2 and washed with saturated NaHCO3 and brine. After the organic layer was dried and concentrated, the residue was purified by silica gel chromatography [5.0g, hexane-EtOAc (1:1)] to give 20 (51.0mg, 90% overall 3 steps).
1.17 (d, 6-H), 1.20 (s, 3"-CH3), 1.20 (d, 6"-H), 1.28 (d, 6-H), 1.48 (m, 4"-OCH2CH2CH(CH3)2), 1.98 (s, 2'-OCOCH3), 2.18 (br d, 2-H), 2.18 (br d, 2"-Hax), 2.40 (s, 3'-N(CH3)2), 2.43 (br d, 14-H), 2.72 (d, 4"-H), 2.86 (dd, 4-H), 3.59 (dt, 4"-OCH2CH2CH(CH3)2), 3.96 (br d, 18-H), 4.18 (dd, 9-H) 
